Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension

A phase 4 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It enrolled 198 participants.

Also called NCT06041529

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 198 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT06041529
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Active, not recruiting (from the registry)

Technical summary

Registry record NCT06041529. Randomized; no masking; primary purpose treatment. Start 2023-10-18 (actual); primary completion 2026-02-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Study to Evaluate the Efficacy and Safety of TEL/AML/CTD in Elderly Patients With Essential Hypertension
Condition
Essential Hypertension
Intervention (Drug)
Telmisartan/Amlodipine/Chlorthalidone 40/5/12.5 mg
Intervention (Drug)
Telmisartan/Amlodipine/Hydrochlorothiazide 40/5/25 mg
Lead sponsor
Yuhan Corporation (class: industry)

Record details

Record id
cardio:ct-nct06041529
Content hash
c0d0f47061eefa964800a0cb692b1ed56f1aeaf65b115e38adcccc4254eea4d6